药品信息:
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201991710254533.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- 部分中文TNKase处方资料(仅供参考)
【英文名称】TNKase
【适用证】
TNKase(替奈普酶)适用于降低与急性心肌梗死(AMI)相关的死亡率。 AMI症状出现后应尽快开始治疗(见临床研究)
【用法用量】
TNKase(替奈普酶)仅用于静脉内给药。 建议的总剂量不应超过50毫克,并以患者体重为基础。
单次推注剂量应根据患者体重在5秒内给药。 AMI症状发作后应尽快开始治疗(见临床研究)。
患者体重(kg); TNKas e(mg);给药量TNKas(mL)
<60; 30; 6
≥60至<70; 35; 7
≥70至<80; 40; 8
≥80至<90; 45; 9
≥90; 50; 10
仅在临床研究中描述的同时施用肝素和阿司匹林的情况下研究了TNKase的安全性和有效性。
【禁忌】
对于急性心肌梗死患者的TNKas e疗法在以下情况下是禁忌的,因为出血风险增加(警告):
---主动内出血
---脑血管事故史
--- 2个月内颅内或脊柱内手术或创伤
---颅内肿瘤,动静脉畸形或动脉瘤
---已知的出血素质
---严重不受控制的高血压
【INDICATIONS】
TNKase (Tenecteplase) is indicated for use in the reduction of mortality associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms (see CLINICAL STUDIE
【DOSAGE】
TNKase (Tenecteplase) is for intravenous administration only. The recommended total dose should not exceed 50 mg and is based upon patient weight.
A single bolus dose should be administered over 5 seconds based on patient weight. Treatment should be initiated as soon as possible after the onset of AMI symptoms (see CLINICAL STUDIES).
Patient Weight (kg); TNKas e(mg); Volume TNKas e to be administered (mL)
<60; 30; 6
≥60 to <70; 35; 7
≥70 to <80; 40; 8
≥80 to <90; 45; 9
≥90; 50; 10
The safety and efficacy of TNKase have only been investigated with concomitant administration of heparin and aspirin as described in CLINICAL STUDIES.
【CONTRAINDICATIONS】
TNKas e therapy in patients with acute myocardial infarction is contraindicated in the following situations becaus e of an increas ed risk of bleeding (s ee WARNINGS):
---Active internal bleeding
---History of cerebrovas cular accident
---Intracranial or intraspinal surgery or trauma within 2 months
---Intracranial neoplasm, arteriovenous malformation, or aneurysm
---Known bleeding diathesis
---Severe uncontrolled hypertens
--------------------------------------------------------------- 详细处方信息以本药内容附件PDF文件(201991710254533.pdf)的“原文Priscribing Information”为准 --------------------------------------------------------------- |